RCWM
ABBV icon

Royal Capital Wealth Management’s AbbVie ABBV Stock Holding History

Royal Capital Wealth Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.92M Sell
8,831
-811
-8% -$180K 1.2% 22
2025
Q4 		$2.2M Buy
9,642
+6
+0.1% +$1.37K 1.3% 20
2025
Q3 		$2.23M Buy
9,636
+1
+0% +$204 1.37% 19
2025
Q2 		$1.79M Buy
9,635
+13
+0.1% +$2.42K 1.19% 22
2025
Q1 		$2.02M Buy
9,622
+12
+0.1% +$2.33K 1.41% 21
2024
Q4 		$1.71M Sell
9,610
-407
-4% -$74.8K 1.2% 21
2024
Q3 		$1.98M Sell
10,017
-153
-2% -$28.6K 1.4% 19
2024
Q2 		$1.74M Sell
10,170
-84
-0.8% -$13.9K 1.31% 20
2024
Q1 		$1.87M Sell
10,254
-65
-0.6% -$11.2K 1.47% 19
2023
Q4 		$1.6M Sell
10,319
-62
-0.6% -$9.04K 1.38% 19
2023
Q3 		$1.55M Sell
10,381
-138
-1% -$20.3K 1.48% 20
2023
Q2 		$1.42M Sell
10,519
-137
-1% -$20.1K 1.34% 22
2023
Q1 		$1.7M Sell
10,656
-76
-0.7% -$11.6K 1.71% 16
2022
Q4 		$1.73M Buy
10,732
+7
+0.1% +$1.07K 1.84% 15
2022
Q3 		$1.44M Buy
10,725
+179
+2% +$25.7K 1.68% 20
2022
Q2 		$1.61M Buy
10,546
+11
+0.1% +$1.68K 1.75% 18
2022
Q1 		$1.71M Buy
10,535
+300
+3% +$43.6K 1.67% 19
2021
Q4 		$1.39M Buy
+10,235
New +$1.21M 1.34% 21

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Royal Capital Wealth Management's ABBV Position: Q1 2026 in Review

Royal Capital Wealth Management reduced its AbbVie (ABBV) stake by 8.4% in Q1 2026, selling an estimated $180K and leaving 8,831 shares worth $1.92M. The position accounts for 1.2% of the portfolio, ranked #22.

Royal Capital Wealth Management first reported a position in ABBV in Q4 2021 and has held it in 18 quarters since. The position peaked at $2.23M in Q3 2025. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Royal Capital Wealth Management held 8,831 shares of AbbVie worth $1.92M as of Q1 2026.
  • Royal Capital Wealth Management sold 811 AbbVie shares in Q1 2026, an estimated $180K.
  • AbbVie made up 1.2% of Royal Capital Wealth Management's portfolio in Q1 2026, its #22 holding.
  • Royal Capital Wealth Management first reported a position in AbbVie in Q4 2021 and has held it in 18 quarters since.
  • Royal Capital Wealth Management's AbbVie position peaked at $2.23M in Q3 2025.
  • 4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Royal Capital Wealth Management's 13F filing for Q1 2026, filed 15 May 2026.